---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-017132"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T22:32:22.955033+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CervoMed reports Q1 net income $2.5M; DLB trial enrollment on track for Q2 2024

## Summary
- Cash $6.4M as of March 31; plus $50M upfront from private placement closed April 1 provides runway through end 2025.
- RewinD-LB Phase 2b enrollment on track to complete in Q2 2024; topline data expected Q4 2024.
- Net income $2.5M in Q1 vs net loss $0.5M in Q1 2023; operating loss widened to $2.6M from $1.4M.
- Grant revenue from NIA $2.3M in Q1 vs $1.4M; R&D expenses increased to $2.8M.
- Up to $149.4M private placement with leading healthcare investors; $50M gross upfront.

## SEC filing metadata
- accession: 0001437749-24-017132
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774924017132/0001437749-24-017132-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774924017132/crvo20240515_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-017132
- JSON: https://secwatch.observer/filing/0001437749-24-017132.json
- Plain text: https://secwatch.observer/filing/0001437749-24-017132.txt

## Key facts
- Earnings Releases
  CervoMed Inc. reported first quarter ended March 31, 2024 results: net income approximately $2.5 million.
  - Period: first quarter ended March 31, 2024
  - Net income: approximately $2.5 million
  - Result: reported results
  source text: Net income was approximately $2.5 million for the three months ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1053691/000143774924017132/0001437749-24-017132-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.